Activity of bortezomib administered once every 3 weeks for treatment of relapsed multiple myeloma.
Sadek
Ibrahim
I
Dispenzieri
Angela
A
Gertz
Morie A
MA
Kumar
Shaji
S
D000369:Aged, 80 and over; D001897:Boronic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D000069286:Bortezomib; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D011719:Pyrazines / Q000008:administration & dosage / Q000627:therapeutic use*; D012008:Recurrence; D016896:Treatment Outcome
D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib